ArticleLaryngoscope investigative otolaryngology2024
Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection.
Article in Laryngoscope investigative otolaryngology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deciphering the cellular landscape of pathological scars.Burns & trauma · 2026Article
- Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection.Laryngoscope investigative otolaryngology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Objective: In this study, we aimed to evaluate mir-31-5p as a prognostic biomarker of keloid disease (KD) recurrence using a retrospective, treatment naïve, surgical cohort of head and neck KD cases from Henry Ford Health. Methods: Using a tissue microarray, mir-31-5p expression was measured with miRNAscope, and mir-31-5p cell positivity was determined with QuPath. Logistic regression was used to test the association between mir-31-5p positive cells and KD recurrence at 1 year. In an independent dataset, associations between mir-31-5p and messenger RNA (mRNA) expression were assessed. Ingenuity Pathway Analysis identified target genes and pathways impacted by mir-31-5p. Results: Of the 58 KD patients, 42 (72%) received adjuvant triamcinolone injections, and 8 recurred (14%). mir-31-5p was expressed in 48 (83%) specimens. Increasing mir-31-5p expression was associated with decreased risk of recurrence ( Conclusion: Taken together, our data supports the association between mir-31-5p expression and KD recurrence. Its potential as a prognostic biomarker should be further investigated. Level of Evidence: Level 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.